NCE 401
Alternative Names: NCE-401; TU-2218Latest Information Update: 10 Oct 2024
At a glance
- Originator TiumBio
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours; Squamous cell cancer
- No development reported Cancer; Idiopathic pulmonary fibrosis
Most Recent Events
- 04 Oct 2024 Phase-I/II clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in South Korea (PO) (NCT05204862)
- 04 Oct 2024 Phase-I/II clinical trials in Squamous cell cancer (Late-stage disease, Second-line therapy or greater, Monotherapy) in South Korea (PO)
- 01 Jun 2024 Efficacy and adverse events data from a phase Ib/IIa trial in Solid tumours released by TiumBio